DelveInsight’s ‘Axial Spondyloarthritis (AxSpA)—Epidemiology Forecast–2032’ report delivers an in-depth understanding of the axSpA, historical and forecasted epidemiology as well as the axSpA trends in the United States.
Axial Spondyloarthritis (axSpA) Disease Understanding
Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Nr-axSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between nr-axSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of axSpA; hence patients typically present with inflammatory back pain. Other manifestations, such as enthesitis, dactylitis, peripheral arthritis, anterior uveitis, psoriasis, and inflammatory bowel disease, are common. Over time many patients with nr-axSpA develop the structural damage of sacroiliac joints, ultimately progressing to AS; however, some nr-axSpA patients will never advance to this stage. The clinical manifestations for axSpA and nr-axSpA are similar to the patients’ disease burden experience.
Patients with axSpA commonly complain of back pain that starts before 45 years of age. Back pain’s characteristic features include chronicity (>3 months), insidious onset, improvement with exercise, an occurrence at night with improvement upon waking, and no rest. Inflammatory back pain (IBP) criteria are essential in screening for axSpA. Among at-risk patients, the sensitivity of IBP (approximately 70–95%) for axSpA is relatively high (back pain >3 months with onset age).
Continued in the report…..
Axial Spondyloarthritis (axSpA) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axial Spondyloarthritis, Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis scenario in the 7MM countries covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan Axial Spondyloarthritis (axSpA)
Detailed Epidemiology Segmentation
The total prevalent population of axSpA in the 7MM was 3,981,346. These cases are anticipated to increase in during the forecast period [2022–2032].
The highest prevalent cases of axSpA were accounted by the US in 2021, making up to 2,217,315 cases, while the EU5 countries accounted for 1,751,778 cases in the same year.
Among the different types of genes in axSpA, i.e., HLA-B27, and Others (ERAP 1, IL-12, IL-17, and IL-23), the former accounts for a higher number of diagnosed prevalent cases of axSpA (789622) in the EU-5 in 2021.
As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed in males in AS, in comparison to females, in all the 7MM countries
In 2021, 70.90% of the total diagnosed prevalent population of Ankylosing spondylitis (AS) in Japan were male, which is equivalent to 2,903 cases. In comparison, for females, 1,192 cases were observed in 2021.
Japan had 5,000 diagnosed prevalent cases for axSpA in 2021, being the lowest of all other countries in 7MM.
Scope of the Report
The report covers the descriptive overview of AXSPA, explaining its causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the historical and forecasted patient pool covering the United States.
The report assesses the disease risk and burden and highlights the unmet needs of AXSPA.
The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
The report provides the segmentation of the disease epidemiology for the 7MM countries by Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis.
Report Highlights
11-Year Forecast of axSpA
7MM Coverage
Total Prevalent Cases of Axial Spondyloarthritis
Total Diagnosed Prevalent Cases of Axial Spondyloarthritis
Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
Key Questions Answered
What are the disease risk, and burden of axSpA?
What is the historical axSpA patient pool in the 7MM countries?
What would be the forecasted patient pool of axSpA at the 7MM level?
What will be the growth opportunities across the 7MM countries with respect to the patient population pertaining to axSpA?
Out of the above-mentioned countries, which country would have the highest prevalent population of axSpA during the forecast period (2022–2032)?
At what CAGR the population is expected to grow across the 7MM countries during the forecast period (2022–2032)?
Reasons to buy
The AXSPA report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the 7MM axSpA epidemiology forecast.
The axSpA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The axSpA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2019–2032
- 1 Key Insights
- 2 Report Introduction
- 3 Axial Spondyloarthritis (axSpA) Epidemiology Overview at a Glance
- 3.1 Patient Share (%) Distribution of Axial Spondyloarthritis by class (axSpA) in 2019
- 3.2 Patient Share (%) Distribution of Axial Spondyloarthritis by class (axSpA) in 2032
- 4 Axial Spondyloarthritis (axSpA): Future Prospects
- 5 Executive Summary of Axial Spondyloarthritis (axSpA)
- 6 Key Events
- 7 Introduction
- 7.1 Cause
- 7.2 Etiology
- 7.2.1 Endogenous Factors
- 7.2.2 Exogenous Factors
- 7.3 Risk Factors
- 7.3.1 Gender
- 7.3.2 Family History
- 7.3.3 Genetic Predisposition
- 7.3.4 Age
- 7.4 Signs and symptoms
- 7.5 Genetics – an insight into the pathogenesis
- 7.5.1 HLAB27 causing AS
- 7.5.2 Antigen processing and presentation
- 7.5.3 IL-17 and type 3 immunity in AS
- 7.5.4 IL-17
- 7.5.5 IL-23 signaling
- 7.5.6 Targeting type-3 immunity in AS
- 7.6 Biomarkers
- 7.6.1 Genetic biomarkers
- 7.6.2 Markers for inflammation
- 7.6.3 Cartilage Turnover Markers
- 7.6.4 Other Biomarkers
- 7.7 Clinical Manifestations
- 7.7.1 Peripheral arthritis
- 7.7.2 Enthesitis
- 7.7.3 Restriction of spinal mobility
- 7.7.4 Hip and shoulder joints
- 7.7.5 Dactylitis
- 7.7.6 Extra-articular locations
- 7.8 Diagnosis
- 7.8.1 Blood tests
- 7.8.2 Imaging tests
- 7.9 Differential Diagnosis
- 7.1 Underdiagnoses and Diagnostic Delay
- 7.11 Diagnostic Criteria
- 7.12 New York Classification Criteria: Diagnostic Criteria for AS
- 8 Treatment and Management
- 8.1 Therapeutic treatment
- 8.1.1 Therapy
- 8.1.2 Surgery
- 8.1.3 Lifestyle and home remedies
- 8.2 Treatment Guidelines
- 8.2.1 ASAS-EULAR management recommendations for axial spondyloarthritis
- 8.2.2 Recommendations for the treatment of axial spondyloarthritis
- 8.2.3 APLAR axial spondyloarthritis treatment recommendations
- 8.2.4 American College of Rheumatology (ACR ) Recommendations for the treatment of axial spondyloarthritis
- 8.2.5 National Institute For Health and Care Excellence (NICE) UK, Guidelines on Diagnosis and Treatment of Spondyloarthritis
- 9 Epidemiology and Patient Population
- 9.1 Key Findings
- 9.2 Epidemiology Methodology
- 9.3 Assumptions and Rationales: 7MM
- 9.4 Total Prevalent Cases of Axial Spondyloarthritis in the 7MM
- 9.5 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the 7MM
- 9.6 United States
- 9.6.1 Total Prevalent Cases of Axial Spondyloarthritis in the United States
- 9.6.2 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
- 9.6.3 Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
- 9.6.4 Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
- 9.6.5 Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States
- 9.7 Europe
- 9.7.1 Total Prevalent Cases of Axial Spondyloarthritis in EU-5
- 9.7.2 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5
- 9.7.3 Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5
- 9.7.4 Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5
- 9.7.5 Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in EU-5
- 9.8 Japan
- 9.8.1 Total Prevalent Cases of Axial Spondyloarthritis in Japan
- 9.8.2 Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan
- 9.8.3 Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan
- 9.8.4 Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan
- 9.8.5 Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan
- 10 Appendix
- 10.1 Bibliography
- 10.2 Report Methodology
- 11 DelveInsight Capabilities
- 12 Disclaimer
- 13 About DelveInsight
- Table 1: Summary of AxSpA Epidemiology (2019–2032)
- Table 2: Key Events
- Table 3: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2019−2032)
- Table 4: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2019−2032)
- Table 5: Total Prevalent Cases of Axial Spondyloarthritis in the United States, in “00” (2019−2032)
- Table 6: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States , in “00” (2019-2032)
- Table 7: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States, in “00” (2019-2032)
- Table 8: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States, in “00” (2019-2032)
- Table 9: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States, in “00” (2019-2030)
- Table 10: Total Prevalent Cases of Axial Spondyloarthritis in the EU-5, in “00” (2019−2032)
- Table 11: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5, in “00” (2019−2032)
- Table 12: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5, in “00” (2019-2032)
- Table 13: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5, in “00” (2019-2032)
- Table 14: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in EU-5 in “00” (2019-2032)
- Table 15: Total Prevalent Cases of Axial Spondyloarthritis in Japan, in “00” (2019−2032)
- Table 16: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan, in “00” (2019-2032)
- Table 17: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan, in “00” (2019-2030)
- Table 18: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan, in “00” (2019-2032)
- Table 19: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan, in “00” (2019-2032)
- Figure 1: Total Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019-2032)
- Figure 2: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the 7MM (2019-2032)
- Figure 3: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2019-2032)
- Figure 4: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2019-2032)
- Figure 5: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2019-2032)
- Figure 6: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2019-2032)
- Figure 7: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2019-2032)
- Figure 8: Total Prevalent Cases of Axial Spondyloarthritis in the EU-5 (2019-2032)
- Figure 9: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5 (2019-2030)
- Figure 10: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5 (2019-2032)
- Figure 11: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the EU-5 (2019-2032)
- Figure 12: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in EU-5 (2019-2032)
- Figure 13: Total Prevalent Cases of Axial Spondyloarthritis in Japan (2019-2032)
- Figure 14: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan (2019-2032)
- Figure 15: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan (2019-2032)
- Figure 16: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan (2019-2032)
- Figure 17: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in Japan (2019-2032)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook